<Back to Therapeutic Areas


Pathophysiology of COVID-19 (2:25)

An Evolving Target: Variants of SARS-Cov-2 (4:30)

GSK COVID Therapeutics will have a presence at the meetings listed below. Please visit us at our scientific booths to view our scientific information.

Meet Us

SHM | May 3-7, 2021 | Virtual

ATS | May 14-19, 2021 | Virtual

AAEM21 | June 20-24, 2021 | St. Louis, MO | Virtual

NMA | July 17-20, 2021 | Virtual

AAFP | Sept 28-Oct 2, 2021 | Virtual

IDWeek | Sept 29-Oct 3, 2021 | San Diego, CA

Critical Concepts in Emergency Medicine | Sept 30-Oct 2, 2021 | New Orleans, LA

CHEST | Oct 24-27, 2021 | Vancouver, Canada

ACEP | Oct 25-28, 2021 | Boston, MA

ACAAI | Nov 4-8, 2021 | New Orleans, LA

ACR | Nov 5-9, 2021 | San Francisco, CA

AARC | Nov 6-9, 2021 | Phoenix, AZ

If you have a question, please contact the GSK COVID Contact Center.

9 AM - 6 PM ET, Monday - Friday, with after hours pager service available
Speak with a GSK COVID Medical Expert

GSK is sharing publicly-available resources from health agencies and various organizations to help your patients, practices, and communities. The opinions, statements, and recommendations presented are solely those of the authors of articles and not controlled or endorsed by GSK.

View our ongoing, innovative research to the COVID-19 Pandemic.

Phase II Phase III Phase IV

OSCAR: Investigating Otilimab in Patients with Severe Pulmonary COVID-19 Related Disease


COMET-ICE: VIR-7831 for the Early Treatment of COVID-19 in Outpatients


COMET-PEAK: Safety, Tolerability, and Pharmacokinetics of Second Generation VIR-7831 in Non-hospitalized Patients with mild to Moderate COVID-19


BLAZE-4: A Study of Immune System Proteins in Participants with Mild to Moderate COVID-19 Illness sponsored by Eli Lilly and Company

  • *VIR-7831 is being developed in a collaboration between GSK and Vir Biotechnology

Antibody Collaborations (0.27)

COVID-19 Immunology (0.29)

What are Variants (0.44)

What is Antibody Therapy (0.42)

  Contact Us